Scilex Holding Co

For the period ended Mar 31, 2026. Filed May 20, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 20, 2026

SCLX$1.61-7.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(In thousands)

	Three Months Ended March 31,
	2026	2025
Operating activities
Net loss including noncontrolling interest	$(45,650)	$(26,080)
Adjustments to reconcile net loss to net cash proceeds from operating activities:
Depreciation and amortization	2,869	1,003
Amortization of debt issuance costs and debt discount	1,028	—
Non-cash operating lease cost	643	176
Non-cash interest expense for deferred consideration	324	—
Stock-based compensation	3,629	3,314
Gain on derivative liability	(25,709)	(10,409)
Loss on compound derivative of Scilex-St. James Loans	21,829	—
Financing costs and allocated expense for financial instruments at fair value	—	4,057
In-process research and development expense	—	566
Realized loss on securities	3,071	—
Change in fair value of debt and liability instruments	2,797	6,114
Unrealized loss on digital assets	18,064	—
Unrealized loss on EMI	31,710	—
Realized (gain) loss on EMI	(42,338)	—
Allowances for expected credit losses	800	—
Non-cash revenue	(1,131)	—
Gain from property in kind dividend	(525)	—
Other	1,614	38
Changes in operating assets and liabilities:
Accounts receivables, net	4,597	15,823
Inventory	257	(584)
Prepaid expenses and other	614	129
Other long-term assets	(605)	—
Accounts payable	15,812	5,128
Accrued payroll	631	149
Accrued expenses	(7,805)	841
Accrued rebates and fees	15,758	5,912
Other liabilities	(3,394)	(170)
Other long-term liabilities	3	—
Net cash (used for) proceeds from operating activities	(1,107)	6,007
Investing activities
Cash paid for in-process research and development, net	—	(200)
Purchase of patent	(2,900)	—
Acquisition consideration paid in cash for Romeg intangible asset acquisition	(150)	(150)
Payment made for PA OPS investment	(200)	—
Purchases of Bitcoin	(18,698)	—
Repayments on promissory note	(750)	—
Purchase of preferred shares of Vivasor	(299)	—
Issuance of convertible note receivable for Qscan	(20,000)	—
Sale of Datavault shares for cash, net	31,392	—
Payment made for Datavault Licenses	(500)	—
Sale of Marketable Securities	2,945	—
Purchase of convertible promissory note from Denali	—	(45)
Net cash used for investing activities	(9,160)	(395)
Financing activities
Repayment of Tranche B Note	(6,319)	—
Payments on purchased revenue liability	(794)	—
Payments for Vivasor debt	(745)	—
Acquisition of controlling interest in Vivasor	1,500	—
Repayment of Tranche B Notes principal and interest	—	(1,596)
Payments on purchased revenue liability	—	(797)
Transaction costs paid in connection with share repurchase	—	(396)
Excise tax paid in connection with share repurchase	—	(200)
Proceeds from issuance of St James Loan, net of issuance costs	15,502	—
Transaction costs paid related to Semnur Business Combination	—	(95)
Net cash provided by (used for) financing activities	9,144	(3,084)
Effect of exchange rate changes on cash	(481)	—
Net change in cash and cash equivalents	(1,604)	2,528
Cash and cash equivalents at beginning of period	4,955	3,272
Cash and cash equivalents at end of period	$3,351	$5,800
Non-cash investing and financing activities
Settlement of St James Loans for Datavault shares	$59,366	$—
Purchase of preferred shares	$750	$—
Prepayment related to Q Scan investment	$2,500	$—
Stock dividend declared in 2024, and canceled in February 2026	$1	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.